Abstract |
Thoracic endovascular aortic repair ( TEVAR) was proved to be effective in thoracic descending aortic aneurysm (TDAA) repair in 1994 and approved by the FDA in 2005. Since then, TEVAR has become the first-line, recommended treatment for intact or ruptured DTAA or as a bridge to definitive open surgical repair in connective tissue disease. TEVAR has decreased perioperative morbidity and mortality compared to open surgery due to the lack of thoracotomy, aortic cross-clamping and left heart bypass. Improvement in materials, manufacturing and device delivery systems have allowed for the expansion of indications. Thoughtful and accurate pre-procedure planning is the hallmark of successful TEVAR. Familiarization and adherence to the instructions for use for an aortic device will give the best possible chance of success.
|
Authors | A Claire Watkins, Alex Dalal, Jason T Lee, Michael D Dake |
Journal | Cardiovascular and interventional radiology
(Cardiovasc Intervent Radiol)
Vol. 43
Issue 12
Pg. 1770-1778
(Dec 2020)
ISSN: 1432-086X [Electronic] United States |
PMID | 32449019
(Publication Type: Journal Article, Review)
|
Topics |
- Aortic Aneurysm, Thoracic
(surgery)
- Blood Vessel Prosthesis Implantation
(methods)
- Endovascular Procedures
(methods)
- Humans
- Reoperation
- Time Factors
|